Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 750M 656M 605M 558M 1.05B 72.22B 1.07B 7.23B 2.84B 35.36B 2.82B 2.75B 122B P/E 2026 *
11.5x
P/E 2027 * 11.7x
Enterprise Value 750M 656M 605M 558M 1.05B 72.22B 1.07B 7.23B 2.84B 35.36B 2.82B 2.75B 122B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 2.27x
Free-Float
96.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-2.71%
1 week-4.72%
Current month+3.63%
1 month+23.18%
3 months+25.01%
6 months+8.16%
Current year-5.35%
1 week 40.01
Extreme 40.01
43.34
1 month 33.64
Extreme 33.64
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 18.8
Extreme 18.8
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Chief Tech/Sci/R&D Officer 65 2026-06-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
6/22/26 Sell

Director

-2,500 0.0135%
6/17/26 Free

Compliance Officer

7,394 0.0400%
Change 5-day change 1-year change 3-year change Capi.($)
-2.71%-4.72%+115.64%+209.47% 750M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.33%+0.01%+37.05%+69.52% 357.58B
Weighted average by Cap. +0.37%+0.02%+37.40%+79.70%

Financials

2026 *2027 *
Net sales 277M 242M 223M 206M 388M 26.63B 396M 2.67B 1.05B 13.04B 1.04B 1.02B 44.91B 331M 289M 267M 246M 464M 31.86B 474M 3.19B 1.25B 15.6B 1.24B 1.22B 53.72B
Net income 70.19M 61.37M 56.64M 52.18M 98.41M 6.76B 101M 677M 266M 3.31B 264M 258M 11.4B 79.07M 69.13M 63.8M 58.77M 111M 7.61B 113M 763M 300M 3.73B 297M 290M 12.84B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-17 US$40.54 -2.71% 196,505
26-07-16 US$41.67 +1.19% 351,629
26-07-15 US$41.18 +0.02% 224,187
26-07-14 US$41.17 -0.31% 271,746
26-07-13 US$41.30 -2.94% 430,671
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
40.54USD
Average target price
54.20USD
Spread / Average Target
+33.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock